Dr.GuoLiang Yu is a leader in the Chinese and global biopharmaceutical communities as well as an accomplished scientist and serial entrepreneur. His many leadership roles include currently serving as the Chairman and CEO of Apollomics, an innovative US and China based biopharmaceutical company committed to the discovery and development of oncology combination therapies. In recent years he has also been Executive Chairman of Crown Bioscience Inc. which he successfully sold to JSR Corporation, and served as a Venture Partner at OrbiMed, a premier global venture capital firm. Dr. Yu has also personally helped start several companies where he has served in a board and/or advisory role. Earlier in his career, Dr. Yu co-founded Epitomics Inc., an antibody-based biotechnology company where he served as CEO for 10 years prior the company being acquired by Abcam. Dr. Yu is the founding president of the Chinese Biopharmaceutical Association and serves on the boards of BayHelix, CABS, National Foundation of Cancer Research, Ray Wu Memorial Foundation, and University of the Pacific. Dr. Yu’s success is driven by his scientific curiosity and a passion for translating scientific discovery into real products. His challenge is balancing his time between science and business, fun and work, family and community.

Dr. Dewan Zeng is an internationally recognized leader in pharmaceutical product development and business development. She has had over 25 years of leadership experience in global pharmaceutical companies (Gilead, Pfizer and BeiGene). She has been successful in leveraging her technical insights and leadership skills to foster organizational growth. Prior to joining Innoforce, Dr. Zeng was Vice President, Global Head of Search and Evaluation, Business Development at BeiGene, where she played a critical role in several transformative deals between BeiGene and other global pharmaceutical companies. Prior to her business development career, Dr. Zeng was a global program lead for 20 clinical stage assets where she was responsible for clinical and regulatory strategy and oversight of global clinical studies. She supported IND submission for twenty investigational products in the US and NDA approval of three innovative products in US, Europe or China. She is particularly proud of playing a key role in the development of Ranexa (an anti-angina treatment), UCART19 (a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy), and tislelizumab (an anti-PD-1 antibody that has been approved in ten oncology indications in China).
Dr. Zeng obtained her PhD in Biochemistry from University of Virginia and MBA in global business strategy from California State University. Earlier in her career, she was a prolific researcher and has over 50 publications in peer-reviewed journals including NATURE, PNAS and Journal of Clinical Investigation. At Innoforce, Dr. Zeng and the leadership team are building advanced technology platforms to enable our partners to develop more effective medicines for patients around the world.

Dr. Yuling Li is the co-founder and President of Innoforce Pharmaceuticals, Prior to Innoforce, Dr. Li was the Sr. Vice President of Process Development and Manufacturing of Apollomics (Foster City, CA and Hangzhou), the R&D Fellow/Director in BioPharmaceutical Development at MedImmune/AstraZeneca (Gaithersburg, MD), the Senior Director in BioPharmaceutical Development at Human Genome Sciences Inc. (now part of GSK, Rockville, MD) and an Associate Scientist at Hoffmann-La Roche Inc. in Nutley, New Jersey. In the past 30 years, Dr. Li led CMC activities for 3 BLA submissions and contributed to 9 approved products plus 30+ biopharmaceuticals through various clinical stages of CMC development. During the course of her career, Dr. Li published 40+ peer-reviewed articles and book chapters and is the inventor for five issued patents. In 2014, Dr. Li received the Rising Star Award from the Healthcare Businesswomen Association. Dr. Li served as the President (2007-2008), Board of Directors, member of the Advisory Board for the Chinese Biopharmaceutical Association-USA (CBA, www.CBA-USA.org), a non-profit professional organization. Dr. Li also co-founded the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (ALL-CABPA) in 2008. She is a BayHelix member.

Dr. Kenneth Carter is a dynamic biotechnology industry executive and scientific leader with deep experience in early-stage company development. He has been involved in starting and guiding several biotechnology companies as a co-founder, advisor, CEO, and/or member of the Board of Directors including NexImmune (NASDAQ: NEXI) which he co-founded and served for many years as Chairman and CEO, and Seneca Biopharma (NASDAQ: SNCA) where he served as Executive Chairman. From 1999 until 2009, Dr. Carter was a co-founder and the CEO of Avalon Pharmaceuticals (NASDAQ: AVRX, now part of AbbVie). Under his leadership, Avalon developed a pipeline of cancer drug candidates based on a novel high-throughput genomic screening technology, and completed an IPO and multiple partnerships with top 10 pharmaceutical companies. Earlier in his career, Dr. Carter was head of gene mapping at Human Genome Sciences, Inc. where he was involved in the discovery of dozens of novel human proteins with therapeutic or diagnostic potential, particularly for the treatment of cancer. Dr. Carter is also engaged in a range of educational and teaching activities and holds an adjunct faculty position at Johns Hopkins University, where he teaches a course titled “Creating a Biotechnology Enterprise”.

Dr. Min Zhu is a well-respected professional in the biopharmaceutical industry, with over 17 years of experience in process development, characterization, and validation support. Prior to joining Innoforce, Dr. Zhu served as Director of Protein Science at Boehringer Ingelheim in Fremont. At BI, she was responsible for CMC strategy and cross-functional alignment from process characterization to BLA submission. In addition, she led the technology development and implementation of a next-generation continuous manufacturing platform. Before that, Dr. Zhu led downstream commercial process development, process characterization and validation for several late-stage biologic pipeline products at MedImmune/AstraZeneca. Dr. Zhu has published more than twenty papers in peer-reviewed journals and is a frequent speaker in international biopharmaceutical conferences. In addition to her leadership in the biopharmaceutical community, Dr. Zhu is also passionate about photography and traveling.